Page last updated: 2024-10-30

lorazepam and Parkinson Disease, Secondary

lorazepam has been researched along with Parkinson Disease, Secondary in 3 studies

Lorazepam: A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.

Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19902 (66.67)18.7374
1990's1 (33.33)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Moleman, P1
Schmitz, PJ1
Ladee, GA1
Northoff, G1
Wenke, J1
Pflug, B1
Chouinard, G1

Trials

1 trial available for lorazepam and Parkinson Disease, Secondary

ArticleYear
The use of benzodiazepines in the treatment of manic-depressive illness.
    The Journal of clinical psychiatry, 1988, Volume: 49 Suppl

    Topics: Acute Disease; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Basal Ga

1988

Other Studies

2 other studies available for lorazepam and Parkinson Disease, Secondary

ArticleYear
Extrapyramidal side effects and oral haloperidol: an analysis of explanatory patient and treatment characteristics.
    The Journal of clinical psychiatry, 1982, Volume: 43, Issue:12

    Topics: Adolescent; Adult; Age Factors; Aged; Antiparkinson Agents; Basal Ganglia Diseases; Drug Therapy, Co

1982
Increase of serum creatine phosphokinase in catatonia: an investigation in 32 acute catatonic patients.
    Psychological medicine, 1996, Volume: 26, Issue:3

    Topics: Acute Disease; Adult; Antipsychotic Agents; Catatonia; Combined Modality Therapy; Creatine Kinase; D

1996